Marc Ditmarsch
Corporate Officer/Principal at FRAZIER LIFESCIENCES ACQUISITION CORPORATION
Net worth: - $ as of 2024-04-29
Profile
Marc Ditmarsch is currently the Vice President-Research & Development at NewAmsterdam Pharma Holding BV and the Chief Development Officer at NewAmsterdam Pharma Co. NV.
Previously, he worked as a Medical Director at AstraZeneca BV from 2014 to 2016.
He holds a doctorate degree from Vrije Universiteit Amsterdam.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2023-03-21 | 0 ( -.--% ) | - $ | 2024-04-29 |
Marc Ditmarsch active positions
| Companies | Position | Start |
|---|---|---|
| FRAZIER LIFESCIENCES ACQUISITION CORPORATION | Corporate Officer/Principal | 2022-07-31 |
NewAmsterdam Pharma Holding BV
 NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million. | Corporate Officer/Principal | 2019-12-31 |
Former positions of Marc Ditmarsch
| Companies | Position | End |
|---|---|---|
| AstraZeneca BV | Chief Tech/Sci/R&D Officer | 2015-12-31 |
Training of Marc Ditmarsch
| Vrije Universiteit Amsterdam | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| FRAZIER LIFESCIENCES ACQUISITION CORPORATION | Health Technology |
| Private companies | 2 |
|---|---|
| AstraZeneca BV | |
NewAmsterdam Pharma Holding BV
NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million. | Health Technology |
- Stock Market
- Insiders
- Marc Ditmarsch
